RPT193 for Eczema

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Skin Sciences PLLC, Louisville, KY
Eczema+3 More
RPT193 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Phase 2 study of RPT193 in adults with atopic dermatitis

Eligible Conditions

  • Eczema
  • Dermatitis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Eczema

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 16 weeks

16 weeks
Clinical efficacy
Safety as measured by adverse events

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Eczema

Trial Design

4 Treatment Groups

RPT193 400 mg
1 of 4
RPT193 200 mg
1 of 4
RPT193 50 mg
1 of 4
Placebo
1 of 4
Experimental Treatment
Non-Treatment Group

268 Total Participants · 4 Treatment Groups

Primary Treatment: RPT193 · Has Placebo Group · Phase 2

RPT193 400 mg
Drug
Experimental Group · 1 Intervention: RPT193 · Intervention Types: Drug
RPT193 200 mg
Drug
Experimental Group · 1 Intervention: RPT193 · Intervention Types: Drug
RPT193 50 mg
Drug
Experimental Group · 1 Intervention: RPT193 · Intervention Types: Drug
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RPT193
2019
Completed Phase 1
~110

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 16 weeks
Closest Location: Skin Sciences PLLC · Louisville, KY
Photo of louisville 1Photo of louisville 2Photo of louisville 3
2020First Recorded Clinical Trial
2 TrialsResearching Eczema
1 CompletedClinical Trials

Who is running the clinical trial?

RAPT Therapeutics, Inc.Lead Sponsor
4 Previous Clinical Trials
549 Total Patients Enrolled
1 Trials studying Eczema
103 Patients Enrolled for Eczema

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have active AD, according to the revised Hanifin and Rajka criteria.
You have had a 12-month history of AD and had no significant flares in AD for at least 4 weeks before screening.
You have atopic dermatitis covering at least 10% of the body surface area.
Use of emollient(s) at least 2x daily for 1 week prior to baseline.
You have a negative test result for COVID-19.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.